Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.63 |
| ▸ | GSK3B | P49841 | 3/20 | 0.63 |
| ▸ | MAPK6 | Q16659 | 11/20 | 0.56 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012234 | 1.00 | GSK3A (0.63) | GSK3AGSK3BMAPK6IRAK1CCNK | |
| SCHEMBL16012235 | 1.00 | GSK3A (0.63) | GSK3AGSK3BMAPK6IRAK1CCNK | |
| SCHEMBL17435307 | 0.90 | GSK3A (0.52) | GSK3AGSK3BMAPK6IRAK1CCNK | |
| SCHEMBL16012944 | 0.90 | GSK3A (0.52) | GSK3AGSK3BMAPK6IRAK1CCNK | |
| SCHEMBL16012943 | 0.90 | GSK3A (0.52) | GSK3AGSK3BMAPK6IRAK1CCNK | |
| SCHEMBL16013075 | 0.89 | MAPK6 (0.72) | GSK3AGSK3BMAPK6IRAK1EIF2AK4 | |
| SCHEMBL16012143 | 0.88 | GSK3A (0.58) | GSK3AGSK3BMAPK6EIF2AK4 | |
| SCHEMBL16012144 | 0.88 | GSK3A (0.58) | GSK3AGSK3BMAPK6EIF2AK4 | |
| SCHEMBL16015030 | 0.88 | GSK3A (0.58) | GSK3AGSK3BMAPK6EIF2AK4 | |
| Hydrochloric Acid SCHEMBL17435405 | 0.88 | GSK3A (0.57) | GSK3AGSK3BMAPK6EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | claimed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | claimed |
| EP-2964649-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | claimed |
| WO-2014135244-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | claimed |
| US-9855268-B2 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2018-01-02 | — | — | US | disclosed |
| US-9855268-B2 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2018-01-02 | — | — | US | disclosed |
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2964649-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014135244-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | EIF2AK4, GCN1, GTF2I | GSK3A 3256/4885GSK3B 2810/4885MAPK6 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.